Key result
In vitro iron overload reduces contractility and induces arrhythmias via oxidative damage and myosin inhibition.
Why the study?
Isolating the cardiac-specific cellular and molecular mechanisms driving iron overload cardiomyopathy has been challenging because the disease affects multiple interconnected organ systems.
This study establishes new in vitro models of human iron overload cardiomyopathy and reveals that iron overload decreases force production through oxidative damage of sarcomeric proteins and direct inhibition of myosin.
Should not change clinical iron management; extends human engineered tissue models for mechanistic studies.
Iron overload cardiomyopathy (IOC) is a serious heart condition that is caused by elevated levels of systemic iron. IOC is characterized by both systolic and diastolic dysfunction as well as arrhythmias. It has been challenging to isolate the cardiac-specific cellular and molecular mechanisms driving IOC because the disease affects multiple interconnected organ systems. Here, we leverage stem cell technologies, cardiac tissue engineering, and protein reconstitution assays to model key aspects of human IOC in vitro and to probe the cellular and molecular mechanisms driving cardiac dysfunction. We demonstrate that human engineered heart tissues consisting of both cardiomyocytes and cardiac fibroblasts faithfully recapitulate key aspects of the human disease, including reduced systolic function, impaired diastolic function, and increased prevalence of arrhythmogenic events. We demonstrate that while both cardiomyocytes and cardiac fibroblasts show increased intracellular iron levels, leading to reduced viability, cardiomyocytes show higher levels of iron accumulation and higher levels of reactive oxygen species production. Moreover, we show that in a tissue, iron overload has little effect on the action potential kinetics; however, it directly impacts the amplitude and kinetics of the calcium transient, potentially driving arrhythmogenesis. Finally, we demonstrate that iron overload decreases force production, in part, through oxidative damage of sarcomeric proteins and direct iron-based inhibition of myosin. In summary, our results reveal new insights into the cellular and molecular mechanisms of human IOC pathogenesis, and they establish new in vitro models that can be harnessed to faithfully recapitulate key aspects of the human disease phenotype. Highlights Contractile aspects of iron overload cardiomyopathy have been difficult to study in vitro. We developed engineered heart tissues to model key aspects of the human disease. In vitro iron overload reduces contractility and induces arrhythmogenesis. Iron differentially affects cardiomyocytes and cardiac fibroblasts. Iron overload directly impacts the actomyosin contractile apparatus.
No takes yet. Share an insight, caveat, or question.
Modak et al. (2026) studied Iron overload cardiomyopathy. In vitro iron overload was evaluated. In vitro iron overload in human engineered heart tissues reduced contractility and induced arrhythmogenesis via oxidative damage of sarcomeric proteins and direct iron-based inhibition of myosin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: